Market Cap 3.52B
Revenue (ttm) 0.00
Net Income (ttm) -109.36M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.05
Volume 234,600
Avg Vol 538,510
Day's Range N/A - N/A
Shares Out 37.75M
Stochastic %K 61%
Beta 0.87
Analysts Strong Sell
Price Target $118.17

Company Profile

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeost...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 674 9274
Address:
321 Arsenal Street, Suite 101, Watertown, United States
MindyBaxterd
MindyBaxterd Dec. 7 at 2:03 PM
$TWG $TSLA $IRON $QUIK Major players entering the market https://www.linkedin.com/feed/update/urn:li:activity:7402708145581752334?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7402708145581752334%2C7402708620339150848%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287402708620339150848%2Curn%3Ali%3Aactivity%3A7402708145581752334%29
0 · Reply
VeolaYoung
VeolaYoung Dec. 7 at 1:32 PM
$TWG $TSLA $IRON $QUIK Institutional buying
0 · Reply
Braindead83
Braindead83 Dec. 6 at 7:46 PM
$IRON what do we think, excellent data, up 40%
0 · Reply
S_Franconi
S_Franconi Dec. 6 at 5:00 PM
$IRON “We are excited that we continue to see robust hematologic responses to DISC-0974 regardless of background JAK inhibitor therapy,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine. “It is also encouraging to see these hematologic improvements translating into reduced transfusion burden and fatigue. We look forward to advancing this program with the goal of addressing a significant unmet need as anemia is one of the key manifestations of MF and there is currently no therapy approved to treat anemia in this population.” https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-presents-positive-initial-data-rally-mf-phase-2
0 · Reply
justiceforb_85
justiceforb_85 Dec. 6 at 4:19 PM
$IRON awesome data for DISC-0974 in myelofibrosis.
1 · Reply
S_Franconi
S_Franconi Dec. 6 at 2:44 PM
$IRON December 6, 2025 8:00 AM EST Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-presents-positive-initial-data-rally-mf-phase-2
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:34 AM
Actionable Trade Alert for $IRON: Market Context: $IRON is currently trading at $93.79, showing strong momentum but nearing overbought conditions with an RSI of 67.44. The price is above the 30-day MA of 88.68 and the 50-day MA of 82.31, indicating bullish sentiment. Directional Bias: The bullish trend is supported by the price being closer to the 60-day high of 97.11. However, the RSI suggests caution as it approaches overbought territory. Trade Plan: - Suggested Entry: $93.79 - Stop Loss: $90.00 (3.00 points below entry) - Take Profit Targets: 1. Target 1: $96.00 (2.21% ROI) 2. Target 2: $98.00 (4.67% ROI) 3. Target 3: $110.00 (17.24% ROI) This plan allows for a strategic approach to capitalize on potential upward movement while managing risk effectively. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:09 PM
Actionable Trade Alert for $IRON: Market Context: $IRON is currently trading at $93.79, showing strong momentum but nearing overbought conditions with an RSI of 67.44. The price is above the 30-day MA of 88.68 and the 50-day MA of 82.31, indicating bullish sentiment. Directional Bias: The bullish trend is supported by the price being closer to the 60-day high of 97.11. However, the RSI suggests caution as it approaches overbought territory. Trade Plan: - Suggested Entry: $93.79 - Stop Loss: $90.00 (3.00 points below entry) - Take Profit Targets: 1. Target 1: $96.00 (2.21% ROI) 2. Target 2: $98.00 (4.67% ROI) 3. Target 3: $110.00 (17.24% ROI) This plan allows for a strategic approach to capitalize on potential upward movement while managing risk effectively. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 2:49 AM
$IRON looking forward to update of DISC-0974 in MF this weekend.
1 · Reply
Smellmahass
Smellmahass Dec. 2 at 3:58 PM
$RXRX Which on of these 2 will most likely move bigger on Monday? $IRON both have resdouts.
0 · Reply
Latest News on IRON
Disc Medicine to Participate in Upcoming Investor Conferences

Oct 31, 2025, 8:30 AM EDT - 5 weeks ago

Disc Medicine to Participate in Upcoming Investor Conferences


Disc Medicine (IRON) Q2 Loss Widens 109%

Aug 7, 2025, 12:24 PM EDT - 4 months ago

Disc Medicine (IRON) Q2 Loss Widens 109%


Disc Medicine Appoints Nadim Ahmed to its Board of Directors

Jul 14, 2025, 8:30 AM EDT - 5 months ago

Disc Medicine Appoints Nadim Ahmed to its Board of Directors


Disc Medicine: Forging Ahead In Hematology

Apr 9, 2025, 7:13 AM EDT - 8 months ago

Disc Medicine: Forging Ahead In Hematology


Disc Medicine Announces Underwritten Offering of Common Stock

Jun 14, 2024, 8:03 AM EDT - 1 year ago

Disc Medicine Announces Underwritten Offering of Common Stock


FDA Grants Orphan Drug Designation to 9MW3011

Feb 20, 2024, 9:00 AM EST - 1 year ago

FDA Grants Orphan Drug Designation to 9MW3011


MindyBaxterd
MindyBaxterd Dec. 7 at 2:03 PM
$TWG $TSLA $IRON $QUIK Major players entering the market https://www.linkedin.com/feed/update/urn:li:activity:7402708145581752334?commentUrn=urn%3Ali%3Acomment%3A%28activity%3A7402708145581752334%2C7402708620339150848%29&dashCommentUrn=urn%3Ali%3Afsd_comment%3A%287402708620339150848%2Curn%3Ali%3Aactivity%3A7402708145581752334%29
0 · Reply
VeolaYoung
VeolaYoung Dec. 7 at 1:32 PM
$TWG $TSLA $IRON $QUIK Institutional buying
0 · Reply
Braindead83
Braindead83 Dec. 6 at 7:46 PM
$IRON what do we think, excellent data, up 40%
0 · Reply
S_Franconi
S_Franconi Dec. 6 at 5:00 PM
$IRON “We are excited that we continue to see robust hematologic responses to DISC-0974 regardless of background JAK inhibitor therapy,” said John Quisel, J.D., Ph.D., President and Chief Executive Officer of Disc Medicine. “It is also encouraging to see these hematologic improvements translating into reduced transfusion burden and fatigue. We look forward to advancing this program with the goal of addressing a significant unmet need as anemia is one of the key manifestations of MF and there is currently no therapy approved to treat anemia in this population.” https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-presents-positive-initial-data-rally-mf-phase-2
0 · Reply
justiceforb_85
justiceforb_85 Dec. 6 at 4:19 PM
$IRON awesome data for DISC-0974 in myelofibrosis.
1 · Reply
S_Franconi
S_Franconi Dec. 6 at 2:44 PM
$IRON December 6, 2025 8:00 AM EST Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-presents-positive-initial-data-rally-mf-phase-2
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 6 at 3:34 AM
Actionable Trade Alert for $IRON: Market Context: $IRON is currently trading at $93.79, showing strong momentum but nearing overbought conditions with an RSI of 67.44. The price is above the 30-day MA of 88.68 and the 50-day MA of 82.31, indicating bullish sentiment. Directional Bias: The bullish trend is supported by the price being closer to the 60-day high of 97.11. However, the RSI suggests caution as it approaches overbought territory. Trade Plan: - Suggested Entry: $93.79 - Stop Loss: $90.00 (3.00 points below entry) - Take Profit Targets: 1. Target 1: $96.00 (2.21% ROI) 2. Target 2: $98.00 (4.67% ROI) 3. Target 3: $110.00 (17.24% ROI) This plan allows for a strategic approach to capitalize on potential upward movement while managing risk effectively. https://privateprofiteers.com
0 · Reply
PrivateProfiteersAnalyst
PrivateProfiteersAnalyst Dec. 5 at 11:09 PM
Actionable Trade Alert for $IRON: Market Context: $IRON is currently trading at $93.79, showing strong momentum but nearing overbought conditions with an RSI of 67.44. The price is above the 30-day MA of 88.68 and the 50-day MA of 82.31, indicating bullish sentiment. Directional Bias: The bullish trend is supported by the price being closer to the 60-day high of 97.11. However, the RSI suggests caution as it approaches overbought territory. Trade Plan: - Suggested Entry: $93.79 - Stop Loss: $90.00 (3.00 points below entry) - Take Profit Targets: 1. Target 1: $96.00 (2.21% ROI) 2. Target 2: $98.00 (4.67% ROI) 3. Target 3: $110.00 (17.24% ROI) This plan allows for a strategic approach to capitalize on potential upward movement while managing risk effectively. https://privateprofiteers.com
0 · Reply
justiceforb_85
justiceforb_85 Dec. 4 at 2:49 AM
$IRON looking forward to update of DISC-0974 in MF this weekend.
1 · Reply
Smellmahass
Smellmahass Dec. 2 at 3:58 PM
$RXRX Which on of these 2 will most likely move bigger on Monday? $IRON both have resdouts.
0 · Reply
Smellmahass
Smellmahass Dec. 2 at 12:26 AM
$IRON They will release data on 6th of December about phase 2 Anaemia? Or the data already dropped?
0 · Reply
Smellmahass
Smellmahass Dec. 1 at 5:34 PM
$IRON PT for phase 2 anamiea data next week? I expect the data to be dropped weekend or Monday premarket.
0 · Reply
Doozio
Doozio Nov. 25 at 7:27 PM
Trying to find a $PHAT setup with $IRON Mike in the $XBI as long as no faatch bomb lands 🐒🍌🧠⏰♾️
0 · Reply
MaverikIT
MaverikIT Nov. 24 at 7:52 PM
$IRON +1.84 - eyeing 52wk$ again
0 · Reply
justiceforb_85
justiceforb_85 Nov. 20 at 1:55 AM
$IRON not many watchers on this. Disc-0974 with preliminary promising data with more pending in anemia of MF in patients requiring transfusions on JAKi. I anticipate the data being positive.
1 · Reply
IN0V8
IN0V8 Nov. 10 at 5:19 PM
$IRON Buy Truist Securities raises target price to $114 from $86
1 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 4:23 PM
Truist Securities has updated their rating for Disc Medicine ( $IRON ) to Buy with a price target of 114.
0 · Reply
Braindead83
Braindead83 Nov. 8 at 4:57 PM
$IRON thoughts? Good but not great
2 · Reply
Braindead83
Braindead83 Nov. 8 at 4:25 PM
$IRON anyone have the ASN data from 11am eastern today?
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 7 at 1:05 PM
$VRTX $IRON require u due to r CELL theme coding for markets
0 · Reply
d_risk
d_risk Nov. 6 at 4:46 PM
$IRON - Disc Medicine Inc. Common Stock - 10Q - Updated Risk Factors IRON’s 10-Q risk factors for 2025 spotlight its limited operating history, rising net losses, and ongoing R&D-to-commercialization challenges; risks now detail open-label trial biases, reliance on single-source suppliers, expanded tax and internal control vulnerabilities, new fraud and management growth risks, and potential stock price hits from insider sales and analyst coverage. #Biotechnology #CorporateGovernance #SupplyChain #FinancialRisk #R&DChallenges 🟢 Added 🟠 Removed https://d-risk.ai/IRON/10-Q/2025-11-06
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 12:28 PM
Stifel has updated their rating for Disc Medicine ( $IRON ) to Buy with a price target of 125.
0 · Reply